Chestnut Hill, MA, United States of America

Anthony Quinn

USPTO Granted Patents = 14 (Patent Applications = 9)

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

Gloucester, MA (US) (2019 - 2020)
Chestnut Hill, MA (US) (2014 - 2024)

Company Filing History:

11 out of 196

Alexion Pharmaceuticals, Inc.

patents

2 out of 25

Synageva Biopharma Corporation

Years Active: 2014-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12076376 - Methods for treating lysosomal acid lipase deficiency in patients (2024-09-03),

2. RE49529 - Methods of treating tissue calcification (2023-05-15),

3. 11560554 - Lysosomal storage disease enzymes (2023-01-24),

4. 11400141 - Methods for treating lysosomal acid lipase deficiency in patients (2022-08-02),

5. 10858638 - Lysosomal storage disease enzymes (2020-12-08),

6. 10557161 - Recombinant human ADA2 and ADA2 fusion proteins and methods for treating ADA2 deficiencies (2020-02-11),

7. 10493135 - Methods of treating tissue calcification (2019-12-03),

8. 10413597 - Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB) (2019-09-17),

9. 10407671 - Lysosomal storage disease enzymes (2019-09-10),

10. 10166274 - Methods for treating lysosomal acid lipase deficiency in patients (2019-01-01),

11. 9579366 - Recombinant human NaGlu protein and uses thereof (2017-02-28),

12. 9540621 - NPP1 fusion proteins (2017-01-10),

13. 8846603 - NPP1 fusion proteins (2014-09-30),

14. 8663631 - Methods for treating lysosomal acid lipase deficiency in patients (2014-03-04),

Title: The Innovative Contributions of Anthony Quinn

Introduction

Anthony Quinn is a notable inventor based in Chestnut Hill, MA (US), recognized for his significant contributions to the field of medical treatments. With a total of 14 patents, he has made strides in addressing critical health issues through innovative methodologies.

Latest Patents

Quinn's latest patents include groundbreaking methods for treating lysosomal acid lipase deficiency in patients. This invention provides methods of treating LAL deficiency by administering a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Additionally, he has developed methods aimed at improving growth and liver function, increasing LAL tissue concentration, and enhancing LAL activity in patients suffering from LAL deficiency. Another significant patent focuses on methods of treating tissue calcification. This invention addresses NPP1 deficiency or NPP1-associated diseases, such as idiopathic infantile arterial calcification, vascular calcification in chronic kidney disease, and more. The method involves administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.

Career Highlights

Throughout his career, Anthony Quinn has worked with prominent companies in the pharmaceutical industry, including Alexion Pharmaceuticals, Inc. and Synageva Biopharma Corporation. His work has been instrumental in advancing therapeutic options for patients with complex medical conditions.

Collaborations

Quinn has collaborated with esteemed colleagues, including Alex J Harvey and Zhinan Xia, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

Anthony Quinn's innovative work and numerous patents reflect his dedication to improving patient outcomes through advanced medical treatments. His contributions continue to influence the landscape of medical research and development.

This text is generated by artificial intelligence and may not be accurate.